Holen Sie sich die Stockscreener-App
21.58
1.12%
0.24
Handel nachbörslich:
21.83
0.25
+1.16%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BAX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$21.34
Offen:
$21.5
24-Stunden-Volumen:
7.38M
Relative Volume:
0.83
Marktkapitalisierung:
$11.10B
Einnahmen:
$10.89B
Nettoeinkommen (Verlust:
$-241.00M
KGV:
-81.25
EPS:
-0.2656
Netto-Cashflow:
$340.00M
1W Leistung:
+9.04%
1M Leistung:
+11.35%
6M Leistung:
-11.08%
1J Leistung:
-35.47%
1-Tages-Spanne:
$20.93
$21.84
1-Wochen-Bereich:
$19.96
$22.08
52-Wochen-Spanne:
$17.40
$37.74
Baxter International Inc Stock (BAX) Company Profile
Firmenname
Baxter International Inc
Sektor
Telefon
(224) 948-2000
Adresse
ONE BAXTER PARKWAY, DEERFIELD, IL
Compare BAX vs ISRG, BDX, MDLN, ALC, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
21.58 | 10.98B | 10.89B | -241.00M | 340.00M | -0.2656 |
|
ISRG
Intuitive Surgical Inc
|
504.05 | 177.40B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
185.39 | 51.91B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
MDLN
Medline Inc
|
49.80 | 39.61B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
ALC
Alcon Inc
|
82.63 | 40.88B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
259.12 | 37.34B | 5.40B | 1.49B | 1.78B | 10.12 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Herabstufung | Argus | Buy → Hold |
| 2025-08-04 | Herabstufung | Stifel | Buy → Hold |
| 2025-08-01 | Herabstufung | Goldman | Buy → Neutral |
| 2025-02-26 | Fortgesetzt | Goldman | Buy |
| 2025-02-24 | Hochstufung | Argus | Hold → Buy |
| 2025-02-20 | Fortgesetzt | Barclays | Overweight |
| 2024-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-12-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-12-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-06-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-18 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-18 | Bestätigt | Raymond James | Outperform |
| 2022-02-18 | Bestätigt | Stifel | Buy |
| 2022-02-18 | Bestätigt | UBS | Neutral |
| 2022-02-18 | Bestätigt | Wells Fargo | Overweight |
| 2022-02-11 | Eingeleitet | Goldman | Neutral |
| 2022-01-07 | Fortgesetzt | Citigroup | Buy |
| 2022-01-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-09-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | Herabstufung | UBS | Buy → Neutral |
| 2020-12-15 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-09-04 | Herabstufung | Argus | Buy → Hold |
| 2020-06-24 | Eingeleitet | Oppenheimer | Outperform |
| 2020-03-19 | Hochstufung | Stifel | Hold → Buy |
| 2020-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-01-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-01-02 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | Hochstufung | Argus | Hold → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-05-17 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-06 | Bestätigt | Citigroup | Neutral |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
Alle ansehen
Baxter International Inc Aktie (BAX) Neueste Nachrichten
Patient Lifting Equipment Market is Going to Boom | Baxter International Inc., ICU Medical, Inc., B. Braun Melsungen AG - openPR.com
The Top 5 Analyst Questions From Baxter's Q4 Earnings Call - Finviz
Global Blood Plasma Derivatives Market Size Projected to Reach $104.30 Billion by 2033; Immunoglobulins Drive Robust 9.08% CAGR – SNS Insider - GlobeNewswire Inc.
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
Anti-Venom Market 2026-2035 Top Key Playres: Baxter - openPR.com
Demystifying Baxter International: Insights From 4 Analyst Reviews - Benzinga
Baxter International Inc (BAX) Shares Up 3.99% on Feb 17 - GuruFocus
BAX: Goldman Sachs Lowers Price Target on Baxter International | - GuruFocus
Baxter Restructuring And Divestiture Plan Tests Turnaround And Valuation Case - Sahm
Baxter International (BAX) Returns To Quarterly Loss And Tests Earnings Recovery Narrative - Sahm
Aug Sectors: Is Baxter International Inc a potential multi baggerJuly 2025 Trade Ideas & Capital Efficiency Focused Strategies - baoquankhu1.vn
Baxter International Inc. (NYSE:BAX) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
UBS Maintains Neutral on BAX Baxter International Inc. Feb 2026 - Meyka
Pale Fire Capital Bets Big on Healthcare With a 2.07 Million Share Baxter International (BAX) Investment - Yahoo Finance
Baxter’s New Decentralized Model Tests Earnings And Valuation Expectations - Yahoo Finance
Baxter International Inc. (BAX) Stock Analysis: Navigating Challenges with a 9.31% Potential Upside - DirectorsTalk Interviews
Quarterly Trades: Does Baxter International Inc outperform in volatile marketsTrend Reversal & Daily Stock Trend Watchlist - baoquankhu1.vn
Why Baxter International Stock Was Tumbling Today - AOL.com
Is Baxter International Inc. stock a top momentum playJuly 2025 Weekly Recap & Real-Time Buy Signal Notifications - mfd.ru
Is Baxter International Inc. stock a momentum leaderJuly 2025 Weekly Recap & Weekly Watchlist of Top Performers - mfd.ru
Baxter Overhaul Shifts To Decentralized Model As Recovery Timelines Extend - simplywall.st
Is Baxter International Inc. stock risky to hold nowProduct Launch & AI Based Buy and Sell Signals - mfd.ru
Baxter International Inc.: How a 90-Year Medtech Veteran Is Rebuilding Its Product Playbook - AD HOC NEWS
Baxter International (NYSE:BAX) Price Target Lowered to $17.00 at The Goldman Sachs Group - MarketBeat
A Quick Look at Today's Ratings for Baxter International Inc(BAX.US), With a Forecast Between $20 to $25 - 富途牛牛
Baxter is the S&P 500’s worst performer today. Earnings were brutal. - MSN
The Truth About Baxter International Inc.: Hidden Healthcare Giant or Total Snooze Stock? - AD HOC NEWS
Baxter lays off 90 employees from hurricane-hit unit - Medical Buyer
Baxter International Earnings Call: Growth Meets Margin Squeeze - The Globe and Mail
BAX Q4 Deep Dive: Mixed Segment Performance and Margin Pressures Shape Outlook - Finviz
Looking Into Baxter International Inc's Recent Short Interest - Benzinga
Barclays Lowers Price Target for Baxter Intl (BAX) While Maintai - GuruFocus
Jefferies Financial Group Has Lowered Expectations for Baxter International (NYSE:BAX) Stock Price - MarketBeat
Barclays Has Lowered Expectations for Baxter International (NYSE:BAX) Stock Price - MarketBeat
Baxter sales up 8% to USD 2.97B in Q4 2025 - Medical Buyer
Baxter International Inc. (NYSE:BAX) Plans Quarterly Dividend of $0.01 - MarketBeat
Baxter International Inc. (NYSE:BAX) Q4 2025 Earnings Call Transcript - Insider Monkey
Baxter International Inc. (NYSE:BAX) Q4 2025 earnings call transcript - MSN
LSV Asset Management Decreases Stake in Baxter International Inc. $BAX - MarketBeat
Baxter's new CEO mired in damage control before he can address long-term problems - Crain's Chicago Business
Baxter International Inc. stock underperforms Thursday when compared to competitors - MSN
Baxter Stock (-16%): Profit Guidance Collapse Triggers De-Risking - Trefis
Decoding Baxter International Inc (BAX): A Strategic SWOT Insigh - GuruFocus
Baxter International Is Quietly Going Off – But Is BAX Stock Really Worth Your Money? - AD HOC NEWS
Baxter International (BAX) Q4 2025 Sales Exceed Expectations, EPS Falls Short - GuruFocus
BAXTER INTERNATIONAL INC SEC 10-K Report - TradingView
Baxter International Inc (BAX) Q4 2025 Earnings Call Highlights: Strong Sales Growth Amidst Margin Pressures - GuruFocus
Baxter stock dives on Q4 EPS miss, company introduces new operating model - massdevice.com
Baxter (BAX) Q4 Earnings Miss, Revenue Surpasses Expectations - GuruFocus
Baxter International: Debt, Margin Pressure, Dreadful FY26 Guidance (Downgrade) (NYSE:BAX) - Seeking Alpha
Baxter International Q4 Earnings Call Highlights - MarketBeat
Finanzdaten der Baxter International Inc-Aktie (BAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.91%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):